AB0436 Do Patients Diagnosed with Chronic Inflammatory Arthropathies Treated with Rituximab Need Retreatment with the Same Dosage in Posterior Cycles? Analysis of the Sustained Response after Retreatment at A Lower Dose

Abstract

BackgroundThe dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two weeks. However, it has recently been...